Megan Olsen, MPH, principal at Avalere, discusses how the impact of small patient populations and other limitations may influence payer conversations about gene and cell therapies.
Megan Olsen, MPH, principal at Avalere, discusses how the impact of small patient populations and other limitations may influence payer conversations about gene and cell therapies.
Transcript
Currently, data on gene and cell therapies shows promise but is limited to small populations and no long-term data exists. How does current data influence payer coverage decisions?
The limitations on data availability right now is certainly playing out. I think one of the inherent challenges in this space is you're dealing with small patient populations. And as a result, you're seeing products launch with more limited trial and data, smaller population sizes and the trials and not much data on the really long-term impacts of these treatments, especially given, you know, the hope. And anticipation is that these treatments have that durable benefit for many years, or potentially over a lifetime. But that really long-term data isn't yet available. So I think there are a few things that we're seeing playing out given this environment. One is that stakeholders, including payers, are looking closely at clinical trial data. Sometimes, in some cases, we've seen differences in FDA label relative to the clinical trial populations. And in those cases, payers are looking to the inclusion exclusion criteria or clinical trial populations to think about coverage decisions, given those data available on that population, whereas the FDA label could potentially be a bit a bit broader. And another one of the implications of this limited data is really driving interest in innovative contracting or innovative financing models. So how can we test through payment that this product is having those intended outcomes for the patient and in those outcomes are durable over a longer term time horizon? So I think this is going to be a theme throughout today's conversation, but a lot of interest in new ways to pay for and finance these treatments while collecting that data over the long term.
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More
Panel Addresses Minority Physician Shortage, Maternal Health at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More